The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TCRX | -75.51% | N/A | N/A | -90% |
| S&P | +12.66% | +85.37% | +13.13% | +58% |
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
No news articles found for TScan Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.51M | 139.4% |
| Gross Profit | $1.74M | 7827.3% |
| Gross Margin | 69.45% | 67.4% |
| Market Cap | $103.28M | -60.9% |
| Market Cap / Employee | $0.49M | 0.0% |
| Employees | 210 | 0.0% |
| Net Income | -$35.71M | -19.5% |
| EBITDA | -$36.29M | -14.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $169.51M | 27.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $88.72M | 2.6% |
| Short Term Debt | $6.90M | 77.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -46.73% | -11.9% |
| Return On Invested Capital | -50.84% | -1.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$33.89M | -15.7% |
| Operating Free Cash Flow | -$32.46M | -16.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.71 | 0.32 | 0.39 | 0.58 | -49.60% |
| Price to Sales | 130.40 | 40.48 | 27.02 | 28.05 | -55.57% |
| Price to Tangible Book Value | 0.71 | 0.32 | 0.39 | 0.58 | -49.60% |
| Enterprise Value to EBITDA | -4.85 | -0.68 | -1.76 | -4.06 | -68.71% |
| Return on Equity | -65.1% | -78.9% | -63.3% | -76.4% | 36.68% |
| Total Debt | $97.38M | $97.04M | $96.70M | $95.62M | 5.83% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
